USE OF A COMPOSITION MADE OF MINERAL NUTRIENTS AND OPTIONALLY ACETOGENIC AND/OR BUTYROGENIC BACTERIA IN ORDER TO AVOID OR REDUCE THE FORMATION OF GAS IN THE LARGE INTESTINE OF A MAMMAL AND THE RESULTING ABDOMINAL PROBLEMS

• US 20100247489A1
• Filed: 12/21/2007
• Published: 09/30/2010
• Est. Priority Date: 12/22/2006
• Status: Abandoned Application

• Current Assignee: Roland Saur-Brosch
• Original Assignee: Roland Saur-Brosch
• Inventors: SAUR-BROSCH, Roland
• Application Number:
  US12/520,561
• Publication Number:
  US 20100247489A1
• Time in Patent Office: Days
• US Class Current: 424/93.400
• CPC Class Codes: A61K 31/07 Retinol compounds, e.g. vitamin A retinoic acids A61K31/203
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/04 Sulfur, selenium or tellurium; Compounds thereof
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 1/12 Antidiarrhoeals
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a composition comprising one or more minerals selected from the group consisting of selenium, molybdenum or tungsten, which is carried out galenically or chemically in a way that the mineral or minerals are released completely or in part, just before, during or shortly after arrival at the large intestine, and their use in the manufacture of a medicament for administering to a mammal for the prevention or reduction of gas formation in the colon thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps. Furthermore, the invention relates to a procedure for the isolation of acetogenic and butyrogenic bacterial strains that are suitable for therapeutic purposes outlined above.

Claims

1. Use of a composition comprising one or more minerals selected from the group consisting of selenium, molybdenum or tungsten, which is carried out galenically or chemically in a way that the mineral or minerals are released completely or in part, just before, during or shortly after arrival at the colon, for the manufacture of a medicament for the administration to a mammal for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

4. Use according to claim 1 or 3, characterized in that the chemical implementation is realized by the bonding of the mineral or minerals to chemical compounds, which are not cleavable or absorbable in the small intestine of the mammal, preferably phytic acid, oxalic acid or tannins or tannic acids.

5. Use according to claim 1 or 3, characterized in that the galenic implementation is realized by processing, especially coating and/or grouting, of the composition with at least one pharmaceutical excipient, which is not soluble in the stomach and/or small intestine of the mammal.

6. Use according to claim 1 or 3 or 5, characterized in that the galenic implementation is designed in a way that the mineral or minerals are continuously released over a period of at least three hours, preferably up to 48 hours after passage of the stomach.

7. Use according to any preceding claim, characterized in that the composition further contains one or more strains of acetogenic bacteria.

9. Use according to claim 7, characterized in that at least one of the acetogenic bacteria strains is of Ruminococcus hydrogenotrophicus, Ruminococcus productus, Eubacterium limosum, Clostridium coccoides, or Clostridium formicoaceticum.

10. Use according to any preceding claim, characterized in that the composition further contains one or more strains of butyrogenic bacteria.

11. Use according to claim 10, characterized in that at least one strain of butyrogenic bacteria is selected from the group consisting of:

Fusobacterium, Faecalibacterium, Eubacterium, Clostridium, or a strain isolated by a method according to claims 41 to 44

12. Use according to any of the previous claims, characterized in that the composition also contains vanadium, nickel, iron, sodium, potassium.

13. Use according to any of the previous claims, characterized in that the composition also contains vitamins, especially vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K.

14. Use according to any preceding claim, characterized in that the composition additionally contains one or more nitrogen containing compounds and/or carbohydrate compounds, preferably poorly absorbed by the small intestine of the mammal.

15. Use according to any preceding claim, characterized in that the composition is gradually released in the colon over a period of at least 3 hours, preferably 6 hours, more preferably 12 hours.

16. Use according to any preceding claim, characterized in that the abdominal symptoms are caused by at least one of the following gastrointestinal disorders:

fructose malabsorption, fructose intolerance, lactose intolerance, irritated bowel syndrome, lack of disaccharase, lack of trehalase, short bowel syndrome, irritable bowel syndrome, bloating, meteorism, diarrhea, crohn'"'"'s disease, three month colic, exocrine pancreatic insufficiency, bile acid deficiency, gastric acid deficiency, dysbiosis of the intestinal flora caused by antibiotics, lack of acetogenic bacteria, lack of reductive acetogenic metabolic function of the intestinal flora, celiac disease, sprue, gluten intolerance, histamine intolerance.

17. Use according to any preceding claim, characterized in that the composition contains further enterobacteriaceae, preferably of the species Escherichia coli, either in a separate or the same pharmaceutical preparation, whereas the medicament is instead, and/or additionally designed for the treatment of diarrhea.

18. Use according to any preceding claims, characterized in that the drug instead and/or additionally earmarked to support the reconstruction and regeneration of the intestinal flora and their acetogenic metabolic function subsequent to an antibiotic treatment, hydro-colon therapy and colonic lavages or gastrointestinal infections.

19. Use according to any preceding claim, characterized in that the administration is orally or rectally.

20. Use according to any preceding claim, characterized in that the mammal is human.

42. Procedure according to any of the preceding claims, characterized in that the growth medium is an anaerobic nutrient medium.

43. Procedure according to any of the preceding claims, characterized in that the nutrient medium also contains an acetic acid indicator.

44. Procedure according to any of the preceding claims, characterized in that feces from asymptomatic individuals are used for the isolation.

47. Procedure according to any of the preceding claims, characterized in that the nutrient medium also contains an acetic acid indicator.

48. Procedure according to any of the preceding claims, characterized in that feces from asymptomatic individuals are used for the isolation.

2. Use of a composition comprising tungsten and/or a tungsten compound for the administration to a mammal for the manufacture of a medicament for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

3. Use according to claim 2, characterized in that the composition is designed galenically or chemically in a way that the tungsten and/or the tungsten compound are released completely or in part, just before, during or shortly after arrival at the colon of the mammal.

21. Composition comprising one or more minerals selected from the group consisting of selenium, molybdenum or tungsten, which is carried out galenically or chemically in a way that the mineral or minerals are released completely or in part, just before, during or shortly after arrival at the colon, for the administration to a mammal for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

24. Composition according to claim 21 or 23, characterized in that the chemical implementation is realized by the bonding of the mineral or minerals to chemical compounds, which are not cleavable or absorbable in the small intestine of the mammal, preferably phytic acid, oxalic acid or tannins or tannic acids.

25. Composition according to claim 21 or 23, characterized in that the galenic implementation is realized by processing, especially coating and/or grouting, of the composition with at least one pharmaceutical excipient, which is not soluble in the stomach and/or small intestine of the mammal.

26. Composition according to claim 21 or 23 or 25, characterized in that the galenic implementation is designed in a way that the mineral or minerals are continuously released over a period of at least three hours, preferably up to 48 hours after passage of the stomach.

27. Composition according to one of the claims 21 to 26, characterized in that it further contains one or more strains of acetogenic bacteria.

28. Composition according to claim 27, characterized in that at least one acetogenic bacterial strain is selected from the group consisting of:

Ruminococcus, Eubacterium, Clostridium, or a strain isolated by a method according to claims 45 to 48

29. Composition according to claim 27, characterized in that at least one of the acetogenic bacteria strains is of Ruminococcus hydrogenotrophicus, Ruminococcus productus, Eubacterium limosum, Clostridium coccoides, or Clostridium formicoaceticum.

30. Composition according to one of the claims 21 to 29, characterized in that the it further contains one or more strains of butyrogenic bacteria.

31. Composition according to claim 30, characterized in that at least one strain of butyrogenic bacteria is selected from the group consisting of:

Fusobacterium, Faecalibacterium, Eubacterium, Clostridium, or a strain isolated by a method according to claims 41 to 44

32. Composition according to one of the claims 21 to 31, characterized in that it also contains vanadium, nickel, iron, sodium, potassium.

33. Composition according to one of the claims 21 to 32, characterized in that it also contains vitamins, especially vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K.

34. Composition according to one of the claims 21 to 33, characterized in that the composition additionally contains one or more nitrogen containing compounds and/or carbohydrate compounds, preferably poorly absorbed by the small intestine of the mammal.

35. Composition according to one of the claims 21 to 34, characterized in that it is gradually released in the colon over a period of at least 3 hours, preferably 6 hours, more preferably 12 hours.

36. Composition according to one of the claims 21 to 35, characterized in that the abdominal symptoms are caused by at least one of the following gastrointestinal disorders /:

fructose malabsorption, fructose intolerance, lactose intolerance, irritated bowel syndrome, lack of disaccharase, lack of trehalase, short bowel syndrome, irritable bowel syndrome, bloating, meteorism, diarrhea, crohn'"'"'s disease, three month colic, exocrine pancreatic insufficiency, bile acid deficiency, gastric acid deficiency, dysbiosis of the intestinal flora caused by antibiotics, lack of acetogenic bacteria, lack of reductive acetogenic metabolic function of the intestinal flora, celiac disease, sprue, gluten intolerance, histamine intolerance.

37. Composition according to one of the claims 21 to 36, characterized in that it contains further enterobacteriaceae, preferably of the species Escherichia coli, either in a separate or the same pharmaceutical preparation, whereas the composition is instead, and/or additionally determined for the treatment of diarrhea.

38. Composition according to one of the claims 21 to 37, characterized in that the composition instead and/or additionally determined to support the reconstruction and regeneration of the intestinal flora with acetogenic bacteria subsequent to an antibiotic treatment, hydro-colon therapy and colonic lavages or gastrointestinal infections.

39. Composition according to one of the claims 21 to 38, characterized in that it is determined to be administered orally or rectally.

40. Composition according to one of the claims 21 to 39, characterized in that the mammal is human.

46. Procedure of claim 38, characterized in that the growth medium is an anaerobic nutrient medium.

22. Composition comprising tungsten and/or a tungsten containing compound for the administration to a mammal for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

23. Composition according to claim 22, characterized in that it is designed galenically or chemically in a way that the tungsten and/or the tungsten compound are released completely or in part, just before, during or shortly after arrival at the colon of the mammal.

41. Procedure for the isolation of butyrogenic bacteria from the feces of a mammal comprising the steps:

creating a culture of bacteria from feces samples of an individual in a suitable culture medium containing as the sole energy and carbon source acetic acid.

45. Procedure for isolating acetogenic bacteria from the feces of a mammal comprising the steps:

creating a culture of bacteria from feces samples of an individual in a suitable culture medium containing as the sole energy and carbon source H2 and CO2.

8. Use according to claim 7, characterized in that at least one acetogenic bacterial strain is selected from the group consisting of:

Ruminococcus, Eubacterium, Clostridium, or a strain isolated by a method according to claims 45 to 48